Welcome to Tevogen Bio Holdings Inc.
Reissuing Topline Results from Proof-of-Concept Clinical Trial
Overview
WARREN, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today reissues its previously announced topline results from its Proof-of-Concept (POC) clinical trial designed to evaluate the safety and feasibility of TVGN 489, the company’s first clinical product utilizing the internally developed ExacTcell™ technology, for the treatment of acute high-risk SARS-CoV-2 patients.
TVGN 489
TVGN 489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with precise targets across the SARS-CoV-2 genome, not just the Spike protein. To date, TVGN 489 targets, identified early in the pandemic, persist in the most recent SARS-CoV-2 variants. The open label comparative trial was conducted at Thomas Jefferson University Hospital in Philadelphia to assess the safety and feasibility of TVGN 489 when given at one of four escalating doses.
Clinical Trial Results
Twelve ambulatory patients with newly diagnosed SARS-CoV-2 infection who were at higher risk for infection-related complications due to advanced age or CDC-defined comorbid conditions such as heart, lung, liver, and kidney disease, hypertension, diabetes, cancer, or obesity were treated on the trial. Eighteen patients, who also met these criteria but did not receive TVGN 489 because of lack of HLA matching, were enrolled on an observational arm in the study and treated with standard of care including monoclonal antibodies.
Impact on Individuals
The development of TVGN 489 could potentially provide a new treatment option for individuals who are at high risk for complications from SARS-CoV-2 infection. This genetically unmodified T cell therapeutic has shown promising results in the clinical trial, and if approved for use, it could help improve outcomes for those with advanced age or underlying health conditions.
Global Impact
The success of TVGN 489 in treating acute high-risk SARS-CoV-2 patients could have a significant impact on the world. By providing a targeted and effective treatment for COVID-19, Tevogen Bio Holdings Inc. may contribute to the global efforts to control and ultimately eradicate the virus. This development could potentially save lives and help prevent the spread of SARS-CoV-2 variants.
Conclusion
In conclusion, the reissuing of the topline results from the Proof-of-Concept clinical trial for TVGN 489 marks a significant milestone for Tevogen Bio Holdings Inc. and the field of immunotherapy. The potential of this genetically unmodified T cell therapeutic to treat acute high-risk SARS-CoV-2 patients offers hope for individuals and has the potential to make a positive impact on a global scale. As further research and development continue, we look forward to seeing how this innovative treatment may shape the future of infectious disease therapeutics.
